Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study of MN-166 (ibudilast) in ALS

Trial Profile

A study of MN-166 (ibudilast) in ALS

Planning
Phase of Trial: Phase III

Latest Information Update: 25 Sep 2018

At a glance

  • Drugs Ibudilast (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Sep 2018 According to a MediciNova media release, the company has received a positive feedback from the FDA regarding the Phase III clinical development plan for MN-166 in ALS. The Company has received approval from FDA to proceed with Phase III development of MN-166 for ALS and will finalize the study design according to FDA's feedback.
    • 13 Jul 2018 New trial record
    • 09 Jul 2018 According to a MediciNova media release, the company has requested a meeting with the FDA to discuss the study design.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top